“A European One Health Action Plan against Antimicrobial Resistance (AMR)” [Aon Sláinte Amháin – Plean Gníomhaíochta maidir le frithsheasmhacht in aghaidh ábhair fhrithmhiocróbacha] (COM(2017) 339 final).
"A European One Health Action Plan against Antimicrobial Resistance (AMR)" (COM(2017) 339 final).
Aon Sláinte Amháin – Plean Gníomhaíochta maidir le frithsheasmhacht in aghaidh ábhair fhrithmhiocróbacha (COM(2017) 339 final).
‘A European One Health Action Plan against Antimicrobial Resistance (AMR)’ (COM(2017) 339 final).
cleachtais feirme a choisceann forbairt na frithsheasmhachta in aghaidh ábhair fhrithmhiocróbacha mar a leagtar amach i dteachtaireacht ón gCoimisiún an 29 Meitheamh 2017 dar teideal A European One Health Action Plan against Antimicrobial Resistance (AMR) [Aon Sláinte Amháin – Plean Gníomhaíochta maidir le frithsheasmhacht in aghaidh ábhair fhrithmhiocróbacha (AMR)];
farm practices preventing the development of antimicrobial resistance as set out in Commission communication of 29 June 2017 entitled ‘A European One Health Action Plan against Antimicrobial Resistance (AMR)’;
Teachtaireacht ón gCoimisiún chuig an gComhairle, chuig Parlaimint na hEorpa, Plean Gníomhaíochta Eorpach “Aon Sláinte Amháin” i gcoinne Frithsheasmhacht in aghaidh Ábhair Fhrithmhiocróbacha (COM(2017) 339 final).
Communication from the Commission to the Council and the European Parliament A European One Health Action Plan against Antimicrobial Resistance (AMR) (COM(2017) 339 final).
Teachtaireacht ón gCoimisiún chuig an gComhairle agus chuig Parlaimint na hEorpa dar teideal A European One Health Action Plan against Antimicrobial Resistance (AMR) [Plean Gníomhaíochta Eorpach “Aon Sláinte Amháin” i gcoinne Frithsheasmhacht in aghaidh Fhrithmhiocróbach], COM(2017) 339 final, 29.6.2017.
Communication from the Commission to the Council and the European Parliament, ‘A European One Health Action Plan against Antimicrobial Resistance (AMR)’, COM(2017) 339 final, 29.6.2017.
Ós rud é go dtéann seachadadh agus úsáid táirgí íocshláinte agus go háirithe ábhair fhrithmhiocróbacha ar an mbealach is fearr is féidir chun tairbhe do dhaoine aonair agus do chórais sláinte, ba cheart don Chlár úsáid stuama agus éifeachtúil na dtáirgí sin a chur chun cinn i gcomhréir leis an gcur chuige Aon Sláinte Amháin agus le “Plean Gníomhaíochta Eorpach na hAon Sláinte Amháin i gcoinne na Frithsheasmhachta in aghaidh Ábhair Fhrithmhiocróbacha (AMR)” a leagtar amach i dteachtaireacht ón gCoimisiún an 29 Meitheamh 2017 agus le Cur Chuige Straitéiseach an Aontais Eorpaigh i leith Cógaisíocht sa Chomhshaol a leagtar amach i dteachtaireacht ón gCoimisiún an 11 Márta 2019.Ba cheart don Chlár bearta a chothú freisin chun measúnú agus bainistiú iomchuí na rioscaí comhshaoil a bhaineann le táirgeadh, úsáid agus diúscairt táirgí íocshláinte a neartú.
As the optimal delivery and use of medicinal products, and of antimicrobials in particular, yield benefits for individuals and health systems, the Programme should promote their prudent and efficient use in accordance with the One Health approach, with the ‘European One Health Action Plan against Antimicrobial Resistance (AMR)’ set out in the communication of the Commission of 29 June 2017, and with the ‘European Union Strategic Approach to Pharmaceuticals in the Environment’ set out in the communication of the Commission of 11 March 2019. The Programme should also foster measures to strengthen the assessment and appropriate management of environmental risks associated with the production, use and disposal of medicinal products.
Le hAirteagal 118 de Rialachán (AE) 2019/6, cuirtear leis an teachtaireacht ón gCoimisiún an 29 Meitheamh 2017 dar teideal A European One Health Action Plan against antimicrobial resistance (“AMR”) [Plean Gníomhaíochta Eorpach “Aon Sláinte Amháin” i gcoinne na frithsheasmhachta in aghaidh ábhar frithmhiocróbach], trí chosc agus rialú ar an bhfrithsheasmhacht in aghaidh ábhar frithmhiocróbach a fheabhsú agus trí úsáid níos stuama agus níos freagraí a chur chun cinn i leith úsáid frithmhiocróbach in ainmhithe.
Article 118 of Regulation (EU) 2019/6 builds on the Commission communication of 29 June 2017 entitled ‘A European One Health Action Plan against antimicrobial resistance (‘AMR’)’, by enhancing the prevention and control of antimicrobial resistance and promoting a more prudent and responsible use of antimicrobials in animals.
Tá cuimsiú na n-earraí cogaisíochta comhsheasmhach le Cur Chuige Straitéiseach an Aontais Eorpaigh i leith Cógaisíocht sa Chomhshaol, agus tá cuimsiú an dá hantaibheathach comhsheasmhach le Plean Gníomhaíochta Eorpach “Aon Sláinte Amháin” i gcoinne Frithsheasmhacht in aghaidh Ábhair Fhrithmhiocróbacha, lena dtacaítear le húsáid an liosta faire chun “eolas ar tharlú agus scaipeadh oibreán frithmhiocróbach sa timpeallacht a fheabhsú”.
The addition of the pharmaceuticals is consistent with the EU Strategic Approach to Pharmaceuticals in the Environment, and the inclusion of the two antibiotics is also consistent with the European One Health Action Plan against Antimicrobial Resistance (AMR), which supports the use of the watch list to ‘improve knowledge of the occurrence and spread of antimicrobials in the environment’.
A fhíorú go gcomhlíonann na Ballstáit an reachtaíocht lena rialaítear faireachán ar fhrithsheasmhacht in aghaidh frithmhiocróbach i mbaictéir zónóiseacha agus i mbaictéir chomhthíosacha agus, trína bhíthin sin, rannchuidiú le cur chun feidhme iomlán Phlean Gníomhaíochta Eorpach “Aon Sláinte Amháin” 2017 i gcoinne Frithsheasmhacht in aghaidh Fhrithmhiocróbach.
To verify Member States’ compliance with the legislation governing the monitoring of antimicrobial resistance in zoonotic and commensal bacteria and by this contribute to the full implementation of the 2017 European One Health Action Plan against Antimicrobial Resistance (AMR).